Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Melatonergic agents from ADIR

Sep. 6, 1996

BTG licenses analgesic combination to Forest

Sep. 6, 1996

FDA approves two pain products from Mallinckrodt

Sep. 6, 1996

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

Sep. 6, 1996

New introductions for Faulding's sustained-release morphine product

Sep. 6, 1996

Analgesic and antiinflammatory agents superior to capsaicin

Sep. 6, 1996

Lilly's new AMPA antagonist, LY-311446

Aug. 30, 1996

AChE inhibitor isolated from Penicillium at Kitasato Institute

Aug. 30, 1996

PLA2 role in Alzheimer's disease suggested

Aug. 30, 1996

Basic AD research advances reported

Aug. 30, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...